Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-12-12
2006-12-12
Brusca, John S. (Department: 1631)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S320100, C536S024500
Reexamination Certificate
active
07148202
ABSTRACT:
Filamentous phage particles displaying a ligand on their surface are used to deliver a therapeutic gene to a cell. The ligand is a fusion protein with a phage capsid protein, covalently conjugated to phage particles, or complexed with modified phage particles.
REFERENCES:
patent: 5474935 (1995-12-01), Chatterjee et al.
patent: 5773289 (1998-06-01), Samulski et al.
patent: 5843742 (1998-12-01), Natsoulis et al.
patent: 5871982 (1999-02-01), Wilson et al.
patent: 6054312 (2000-04-01), Larocca et al.
patent: 6323004 (2001-11-01), Kang
patent: 6448083 (2002-09-01), Larocca et al.
patent: 2268942 (1994-01-01), None
patent: WO 92/20791 (1992-11-01), None
patent: WO 95/34648 (1995-12-01), None
patent: WO 96/21007 (1996-07-01), None
patent: WO 97/00271 (1997-01-01), None
patent: WO 97/06435 (1997-02-01), None
patent: WO 98/05344 (1998-02-01), None
patent: WO 98/39482 (1998-09-01), None
“New Living Colors GFP Mammalian Vectors.” Clontechniques, http;//www.clontech.com/archive/JUL96UPD/EGFP.html. [Accessed Jun. 20, 2000].
Barry et al., “Toward cell-targeting gene therapy vectors: Selection of cell-binding peptides from random peptide-presenting phage libraries,”Nature Medicine 2(3):299-305, 1996.
de Kruif et al., “Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library,”Proc. Natl. Acad. Sci. USA 92:3938-3942, 1995.
Dunn, I. S., “Mammalian cell binding and transfection mediated by surface-modified bacteriophage lambda,”Biochimie 78:856-861, 1996.
Fisher et al., “Transduction with Recombinant Adeno-Associated Virus for Gene Therapy Is Limited by Leading-Strand Synthesis,”Journal of Virology 70(1): 520-532, 1996.
Georges et al., “Synthesis of a human insulin gene VII. Synthesis of preproinsulin-like human DNA, its cloning and expression in M13 bacteriophage,”Gene 27:201-211, 1984.
Goldman et al, “Targeted Gene Delivery to Kaposi'Sarcoma Cells Via the Fibroblast Growth Factor Receptor,”Cancer Research 57:1447-1451, 1997.
Greenstein et al. Vectors derived from filamentous phages. In Current Protocols in Molecular Biology (Ausubel et al. Eds.) pp. 1.14.4-1.14.5 John Wiley & Sons, New York, 1993.
Hart et al., “Cell Binding and Internalization by Filamentous Phage Displaying a Cyclic Arg-Gly-Asp-containing Peptide,”Journal of Biological Chemistry 269:12468-12474, 1994.
Hogrete et al., “Cloning in a bacteriophage lambda vector for the display of binding proteins on filamentous phage,”Gene 137:85091, 1993.
Hoogenboom et al., “Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) Heavy and light chains,”Nucleic Acids Research 19(15): 4133-4137, 1991.
Ishiura et al., “Phage Particle-Medicated Gene Transfer to Cultured Mammalian Cells,”Molecular and Cellular Biology 2(6):607-616, 1982.
Jespers et al., “λZLG6: A Phage λ Vector for High-Efficiency Cloning and Surface Expression of cDNA Libraries on Filamentous Phage,”Gene 173(2):179-181, 1996.
Jespers et al., “Surface Experssion and Ligand-Based Selection of cDNAs Fused to Filamentous Phage Gene VI,”Bio/Technology 13: 378-382, 1995.
Larocca et al., “Gene Transfer to Mammalian Cells Using Genetically Targeted Filamentous Bacteriophage,”FASEB J. 13:727-734, 1999.
Larocca et al., “Targeted Gene Delivery to Mammalian Cells Via Fibroblast Growth Factor (FGF-2) Display Phage,”Cancer Gene Theraphy 5(6):S10/PD-31, 1998.
Larocca et al., “Targeting Bacteriophage to Mammalian Cell Surface Receptors for Gene Delivery,”Hum. Gene Ther. 9:2393-2399, 1998.
Maruyama et al., “.lambda.foo: A .lambda. phage vector for the expression of foreign proteins,”Proc. Natl. Acad. Sci. USA 91:8273-8277, 1994.
Okayama and Berg, “Bacteriophage Lambda Vector for Transducing a cDNA Clone Library into Mammalian Cells,”Molecular and Cellular Biology 5(5):1136-1142, 1985.
Orkin et al. Report and recommentations of the panel to assess the NIH investment in research on gene therapy. pp. 1-41, 1995, www.nih.gov
ews/panelrep.html.
Pasqualini and Ruoslahti, “Organ targetingin vivousing phage display peptide libraries,”Nature 380:364-366, 1996.
Pasqualini et al., “αν Integrins as receptors for tumor targeting by circulating ligands,”Nature Biotechnology 15542:546, 1997.
Rubenstein et al., “Subtractive hybridization system using single-stranded phagemids with directional inserts,”Nucleic Acids Research 18(16): 4833-4842, 1990.
Russell, S. J., “Peptide-displaying phages for targeted gene delivery?”Nature Medicine 2(3):276-277, 1996.
Sawyer et al., “Methodology for Selection of Human Antibodies to Membrane Proteins from a Phage-Display Library,”Journal of Immunological Methods 204:193-203, 1997.
Soderlind et al., “Phage Display Technology in Antibody Engineering: Design of Phagemid Vectors and in vitroMaturation Systems,”Immunological Reviews 130: 109-124, 1992.
Souriau et al., “A Simple Luciferase Assay for Signal Transduction Activity Detection of Epidermal Growth Factor Displayed on Phage,”Nucleic Acids Research 25(8):1585-1590, 1997.
Voiculescu, “Aspecte ale interrelatiilor bacteriofagi-celule cucariote,”Bacteriologia, Virusologia, Parazitologia, Epidemiologia XXII(3): 141-148, 1977 (+ English Translation).
Wu et al., “Development of a Novel Drug-Delivery System Using Bacteriophage MS2 Capsids,”Biochemical Society Transactions 24:413S, 1996.
Yokoyama-Kobayashi and Kato, “Recombinant f1 Phage Particles Can Transfect Monkey COS-7 Cells by DEAE Dextran Method,”Biochemical and Biophysical Research Communications 192(2):935-939, 1993.
Yokoyama-Kobayashi and Kato, “Recombinant f1 Phage-Mediated Transfection of Mammalian Cells Using Lipopolyamine Technique,”Analytical Biochemistry 223:130-134, 1994.
Baird Andrew
Johnson Wendy
Larocca David
Brusca John S.
Seed IP Law Group PLLC
Selective Genetics Inc.
LandOfFree
Receptor-mediated gene delivery using bacteriophage vectors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Receptor-mediated gene delivery using bacteriophage vectors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Receptor-mediated gene delivery using bacteriophage vectors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3718431